环丝氨酸治疗结核病的临床用药指南

2020-06-10 中国呼吸科专家组(统称) 中国防痨杂志, 2020, 42(6): 533-540.

目前,结核病疫情仍然较为严重。环丝氨酸作为治疗耐药结核病的核心药品,缺乏具体的相关规范性指导意见。中国防痨协会临床试验专业分会、《中国防痨杂志》编辑委员会组织专家通过深入研究与讨论,制定了《环丝氨酸治

中文标题:

环丝氨酸治疗结核病的临床用药指南

发布日期:

2020-06-10

简要介绍:

目前,结核病疫情仍然较为严重。环丝氨酸作为治疗耐药结核病的核心药品,缺乏具体的相关规范性指导意见。中国防痨协会临床试验专业分会、《中国防痨杂志》编辑委员会组织专家通过深入研究与讨论,制定了《环丝氨酸治疗结核病的临床用药指南》(简称“《指南》”)。本《指南》介绍了环丝氨酸的分子结构和作用机制、药效学与药代动力学、药物相互作用、耐药机制、有效性和安全性、特殊人群应用、适应证和禁忌证、剂量用法、不良反应监测与处理、临床应用注意事项等内容,以期指导医护人员规范、合理地使用环丝氨酸。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=环丝氨酸治疗结核病的临床用药指南.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ca03a1c00192063a, title=环丝氨酸治疗结核病的临床用药指南, enTitle=, guiderFrom=中国防痨杂志, 2020, 42(6): 533-540., authorId=0, author=, summary=目前,结核病疫情仍然较为严重。环丝氨酸作为治疗耐药结核病的核心药品,缺乏具体的相关规范性指导意见。中国防痨协会临床试验专业分会、《中国防痨杂志》编辑委员会组织专家通过深入研究与讨论,制定了《环丝氨酸治, cover=https://img.medsci.cn/2020616/1592311652326_2020535.jpg, journalId=0, articlesId=null, associationId=745, associationName=中国呼吸科专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Jun 10 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>目前,结核病疫情仍然较为严重。环丝氨酸作为治疗耐药结核病的核心药品,缺乏具体的相关规范性指导意见。中国防痨协会临床试验专业分会、《中国防痨杂志》编辑委员会组织专家通过深入研究与讨论,制定了《环丝氨酸治疗结核病的临床用药指南》(简称&ldquo;《指南》&rdquo;)。本《指南》介绍了环丝氨酸的分子结构和作用机制、药效学与药代动力学、药物相互作用、耐药机制、有效性和安全性、特殊人群应用、适应证和禁忌证、剂量用法、不良反应监测与处理、临床应用注意事项等内容,以期指导医护人员规范、合理地使用环丝氨酸。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=380, tagName=结核病)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=380, guiderKeyword=结核病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4284, appHits=123, showAppHits=0, pcHits=803, showPcHits=4161, likes=2, shares=14, comments=6, approvalStatus=1, publishedTime=Tue Jun 16 20:51:33 CST 2020, publishedTimeString=2020-06-10, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Tue Jun 16 20:47:49 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Wed Jan 03 05:48:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=环丝氨酸治疗结核病的临床用药指南.pdf)])
环丝氨酸治疗结核病的临床用药指南.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1007180, encodeId=2ca6100e180a0, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90d65504882, createdName=ms5000000620536461, createdTime=Thu Aug 12 08:07:07 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955555, encodeId=b9f4955555e9, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210408/d9c86e48dc104935b49018dbf151b489/3c5c9264eca7469e8954b4a1441c5dc3.jpg, createdBy=e7265478217, createdName=502淘气, createdTime=Fri Apr 09 19:44:06 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917787, encodeId=cb2191e7877d, content=太好了,真是太实用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1d65453855, createdName=ms9000000974543283, createdTime=Mon Jan 18 18:07:50 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917590, encodeId=8c5a91e5904d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:26:37 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
    2021-08-12 ms5000000620536461

    好文章

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1007180, encodeId=2ca6100e180a0, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90d65504882, createdName=ms5000000620536461, createdTime=Thu Aug 12 08:07:07 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955555, encodeId=b9f4955555e9, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210408/d9c86e48dc104935b49018dbf151b489/3c5c9264eca7469e8954b4a1441c5dc3.jpg, createdBy=e7265478217, createdName=502淘气, createdTime=Fri Apr 09 19:44:06 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917787, encodeId=cb2191e7877d, content=太好了,真是太实用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1d65453855, createdName=ms9000000974543283, createdTime=Mon Jan 18 18:07:50 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917590, encodeId=8c5a91e5904d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:26:37 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
    2021-04-09 502淘气

    👍

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1007180, encodeId=2ca6100e180a0, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90d65504882, createdName=ms5000000620536461, createdTime=Thu Aug 12 08:07:07 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955555, encodeId=b9f4955555e9, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210408/d9c86e48dc104935b49018dbf151b489/3c5c9264eca7469e8954b4a1441c5dc3.jpg, createdBy=e7265478217, createdName=502淘气, createdTime=Fri Apr 09 19:44:06 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917787, encodeId=cb2191e7877d, content=太好了,真是太实用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1d65453855, createdName=ms9000000974543283, createdTime=Mon Jan 18 18:07:50 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917590, encodeId=8c5a91e5904d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:26:37 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
    2021-01-18 ms9000000974543283

    太好了,真是太实用了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1007180, encodeId=2ca6100e180a0, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90d65504882, createdName=ms5000000620536461, createdTime=Thu Aug 12 08:07:07 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955555, encodeId=b9f4955555e9, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210408/d9c86e48dc104935b49018dbf151b489/3c5c9264eca7469e8954b4a1441c5dc3.jpg, createdBy=e7265478217, createdName=502淘气, createdTime=Fri Apr 09 19:44:06 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917787, encodeId=cb2191e7877d, content=太好了,真是太实用了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1d65453855, createdName=ms9000000974543283, createdTime=Mon Jan 18 18:07:50 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917590, encodeId=8c5a91e5904d, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:26:37 CST 2021, time=2021-01-17, status=1, ipAttribution=)]